This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales. The company provides revenues guidance for 2021.
AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright
by Zacks Equity Research
AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.
Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III
by Zacks Equity Research
J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.
Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT
by Zacks Equity Research
Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.
Stock Market News for Feb 1, 2021
by Zacks Equity Research
US stock markets closed sharply lower on Friday, recording the worst weekly decline in stocks since October, as speculative trading in a set of small, heavily traded companies, unsettled markets as a result of growing panic among traders.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.
Top Analyst Reports for Apple, Microsoft & Tesla
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Microsoft Corporation (MSFT) and Tesla, Inc. (TSLA).
Personal Income Increased in December
by Zacks Equity Research
Personal Income Increased in December
Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?
by Zacks Equity Research
Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.
Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data
by Mark Vickery
With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.
Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
Zacks Earnings Trends Highlights: JPMorgan, Boeing, 3M, Microsoft and Johnson & Johnson
by Zacks Equity Research
Zacks Earnings Trends Highlights: JPMorgan, Boeing, 3M, Microsoft and Johnson & Johnson
A Positive and Reassuring Earnings Picture
by Sheraz Mian
Estimates for the current and coming quarters are steadily going up, as companies report Q4 results that are mostly better than expected.
A Positive and Reassuring Earnings Picture
by Sheraz Mian
Estimates for the current and coming quarters are steadily going up, as companies report Q4 results that are mostly better than expected.
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Company News for Jan 27, 2021
by Zacks Equity Research
Companies In The News Are: JNJ, MMM, FCX, PII
Home Prices Rose in November
by Zacks Equity Research
Home Prices Rose in November
Housing Charges Economy: +9.5% Case Shiller & DHI's Earnings Beat
by Mark Vickery
Record-low interest rates, along with Americans moving away from the big cities, helped lead the housing formation run.
J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat
by Zacks Equity Research
J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.
Bayer (BAYRY) Gets a Boost With Product Approvals and Deals
by Zacks Equity Research
Bayer (BAYRY) gets a boost as it wins approvals for a few candidates and enters into collaboration agreements.
Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.76% and 3.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?